Various tissue fibroblast types with distinct properties shape the architecture of the specialized niches of the lung (e.g. airways, alveoli, vasculature). In a significant breakthrough, a team led by Gerald Burgstaller and Herbert Schiller from…
INFRAFRONTIER, a leading player in biomedical research infrastructure, headquartered at Helmholtz Munich, was officially declared as a European Research Infrastructure Consortium (ERIC) by the European Commission. This milestone represents a…
Epigenetic changes play important roles in cancer, metabolic and aging-related diseases, but also during loss of resilience as they cause the genetic material to be incorrectly interpreted in affected cells. A major study by scientists at Helmholtz…
A new study led by Helmholtz Munich scientists Ursula Zimber-Strobl and Lothar J. Strobl sheds light on the intricate pathways of B-lymphocyte development during adaptive immune responses. The study, published in Nature Communications, reveals that…
Michael Frieser will take over as the Administrative Managing Director of Helmholtz Munich from March 1st, 2024. With him, the research center has gained an experienced professional in science administration and public management.
Research targeting the insulin-inhibitory receptor, called inceptor, unveils promising avenues for beta cell protection, offering hope for causal diabetes therapy. A novel study in mice with diet-induced obesity demonstrates that the knock-out of…
Awards & Grants, Environmental Health, COMI,
Awards & Grants, Diabetes,
Awards & Grants, Health AI,
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here: